# 510(k) SUMMARY

1. Date:

September 26, 2013

2. 510(K) Number:

k132630

3. Submitter:

Guangzhou Wondfo Biotech Co., Ltd. South China University of Technology Guangzhou, P.R. China 510641

4 Contact person:

Joe Shia   
LSI International Inc.   
504 East Diamond Ave., Suite F Gaithersburg, MD 20878   
Telephone: 240-505-7880   
Fax: 301-916-6213   
Email:shiajl@yahoo.com

SEP 2 7 2013

Device Name:

Wondfo Methamphetamine Urine Test (MET 300) Wondfo Oxazepam Urine Test (BZO 200)

Classification: Class II   

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>CFR #</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DJC</td><td rowspan=1 colspan=1>21 CFR 862.3610 Methamphetamine TestSystem</td><td rowspan=1 colspan=1>Toxicology</td></tr><tr><td rowspan=1 colspan=1>JXM</td><td rowspan=1 colspan=1>21 CFR 862.3170 Benzodiazepine TestSystem</td><td rowspan=1 colspan=1>Toxicology</td></tr></table>

Predicate Devices:

K050394 Medtox Diagnostics Sure-Screen

7.Intended Use

Wondfo Methamphetamine Urine Test (MET 300) is an immunochromatographic assay for the qualitative determination of $\mathrm { D } ( + )$ -Methamphetamine in human urine at a Cut-Off concentration of ${ 3 0 0 } ~ \mathrm { n g / m L }$ . The test is available in a Dip Card format and a Cup format. This product is only intended for prescription use and is not intended for point-of-care use.

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

Wondfo Oxazepam Urine Test (BZO 200) is an immunochromatographic assay for the qualitative determination of Oxazepam in human urine at a Cut-Off concentration of $2 0 0 ~ \mathrm { n g / m L }$ . The test is available in a Dip Card format and a Cup format. This product is only intended for prescription use and is not intended for point-of-care use.

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

# 8 Device Description

Immunochromatographic assays for Methamphetamine and Oxazepam Urine Tests use a lateral flow, one step system for the qualitative detection of $\mathrm { D } ( + )$ -Methamphetamine and Oxazepam (target analyte) in human urine. Each assay uses a monoclonal antibody-dye conjugate against drugs with gold chloride and fixed drug-protein conjugates and anti-mouse IgG polyclonal antibody in membranes. Oxazepam is part of the Benzodiazepine class of drugs of abuse.

9. Substantial Equivalence Information A summary comparison of features of the Wondfo Methamphetamine Urine Test (MET 300) and Wondfo Oxazepam Urine Test (BZO 200) and the predicate device is provided in Table 1.

Table 1: Features Comparison of Wondfo Methamphetamine Urine Test (MET300) and Wondfo Oxazepam Urine Test (BZO 200) and the Predicate Device   

<table><tr><td rowspan=1 colspan=1>Item     3</td><td rowspan=1 colspan=1>        5       9;.Device                   *:</td><td rowspan=1 colspan=1>Predicate - K050394</td></tr><tr><td rowspan=1 colspan=1>Indication(s)for Use</td><td rowspan=1 colspan=1>For the qualitative determination ofdrugs of abuse in human urine. Forprescription use.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>D(+)-Methamphetamine andOxazepam</td><td rowspan=1 colspan=1>D(+)-Methamphetamineand Nordiazepam</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Competitive binding, lateral flowimmunochromatographic assaysbased on the principle of antigenantibody immunochemistry.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Type of Test</td><td rowspan=1 colspan=1>Qualitative to indicate positive ornegative result</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Human Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cut-Off Values</td><td rowspan=1 colspan=1>300 ng/mL(MET) and200 ng/mL (Oxazepam/BZO)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Configurations</td><td rowspan=1 colspan=1>Cup, Dip Card</td><td rowspan=1 colspan=1>Cup</td></tr></table>

10. Test Principle

It is a rapid test for the qualitative detection of $\mathrm { D } ( + )$ -Methamphetamine and Oxazepam in urine samples. It is a lateral flow chromatographic immunoassay. When the absorbent end is immersed into a urine sample, the urine is absorbed into the device by capillary action and mixes with the antibody-dye conjugate, flowing across the pre-coated membrane. At analyte concentration below the target cut off, antibody-dye conjugates bind to the drug-protein conjugate immobilized in the Test Region (T) of the device. This produces a colored test line that indicates a negative result. When analyte concentration is above the cutoff, analyte molecules bind to the antibody-dye conjugate, preventing the antibody-dye conjugate from binding to the drug-protein conjugate immobilized in the Test Region (T) of the device. No colored band shows in the test region, indicating a potentially positive result.

11. Performance Characteristics

1. Analytical Performance

a.Precision

Precision studies were carried out for samples with concentrations of -100%cut off, $- 7 5 \%$ cut off, $- 5 0 \%$ cut off, $- 2 5 \%$ cut off, $+ 2 5 \%$ cut off, $+ 5 0 \%$ cut off , $+ 7 5 \%$ cut off and $+ 1 0 0 \%$ cut off. These samples were prepared by spiking drug in negative samples. Each drug concentration was confirmed by GC/MS. All sample aliquots were blinded labeled by the person who prepared the samples and that person did not take part in the sample testing. For each concentration, tests were performed two runs per day for 25 days. The results obtained are summarized in the following tables.

# Cup Format

MET 300   

<table><tr><td rowspan=1 colspan=1>ResultMET 300</td><td rowspan=1 colspan=1>-100%Cut-off</td><td rowspan=1 colspan=1>-75%Cut-off</td><td rowspan=1 colspan=1>-50%Cut-off</td><td rowspan=1 colspan=1>-25%Cut-off</td><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>+25%Cut-off</td><td rowspan=1 colspan=1>+50%Cut-off</td><td rowspan=1 colspan=1>+75%Cut-off</td><td rowspan=1 colspan=1>+100%Cut-off</td></tr><tr><td rowspan=1 colspan=1>LOT W1171001CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>47+/3-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOTW1171002CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>45+/5-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W1171003CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>46+/4-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

Oxazepam BZO 200   

<table><tr><td rowspan=1 colspan=1>ResultBZO 200</td><td rowspan=1 colspan=1>-100%Cut-off</td><td rowspan=1 colspan=1>-75%Cut-off</td><td rowspan=1 colspan=1>-50%Cut-off</td><td rowspan=1 colspan=1>-25%Cut-off</td><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>+25%Cut-off</td><td rowspan=1 colspan=1>+50%Cut-off</td><td rowspan=1 colspan=1>+75%Cut-off</td><td rowspan=1 colspan=1>+100%Cut-off</td></tr><tr><td rowspan=1 colspan=1>LOT W0970901CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>46÷/4-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W0970902CU</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>46+/4-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W0970903CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>46+/4-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

MET 300   

<table><tr><td rowspan=1 colspan=1>ResultMET 300</td><td rowspan=1 colspan=1>-100%Cut-off</td><td rowspan=1 colspan=1>-75%Cut-off</td><td rowspan=1 colspan=1>-50%Cut-off</td><td rowspan=1 colspan=1>-25%Cut-off</td><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>+25%Cut-off</td><td rowspan=1 colspan=1>+50%Cut-off</td><td rowspan=1 colspan=1>+75%Cut-off</td><td rowspan=1 colspan=1>+100%CCuut-off</td></tr><tr><td rowspan=1 colspan=1>LOT W1171001P</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>44+/6-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W1171002P</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>45+/5-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W1171003P</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+•</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>45+/5-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

Oxazepam BZO 200   

<table><tr><td rowspan=1 colspan=1>ResultBZO 200</td><td rowspan=1 colspan=1>-100%Cut-off</td><td rowspan=1 colspan=1>-75%Cut-off</td><td rowspan=1 colspan=1>-50%Cut-off</td><td rowspan=1 colspan=1>-25%Cut-off</td><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>+25%Cut-off</td><td rowspan=1 colspan=1>+50%Cut-off</td><td rowspan=1 colspan=1>+75%Cut-off</td><td rowspan=1 colspan=1>+100%Cut-off</td></tr><tr><td rowspan=1 colspan=1>LOT W0970901P</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>45+/5-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W0970902P</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>46+/4-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W0970903P</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>45+/5-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

b. Linearity Not applicable c. Stability

The test devices are stable at $4 { \cdot } 3 0 ^ { \circ } \mathrm { C }$ for 18 months based on the accelerated stability study at $5 0 \mathrm { { ^ \circ C } }$ and real time stability determination at both $4 \%$ and $3 0 ^ { \circ } \mathbf { C }$ .

d. Cut-off

A total of 150 samples equally distributed at concentrations of $- 5 0 \%$ Cut-Off; $- 2 5 \%$ Cut-Off; Cut-Off; $+ 2 5 \%$ Cut-Off; $+ 5 0 \%$ Cut-Off were tested using three different lots of each device by three different operators. Results were all positive at and above $+ 2 5 \%$ Cut-off and all negative at and below $- 2 5 \%$ Cut-off for both Methamphetamine and Oxazepam. The following cut-off values for the test devices have been verified.

<table><tr><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Cut-off(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Wondfo Methamphetamine Urine Test (MET300)</td><td rowspan=1 colspan=1>D(+)-Methamphetamine</td><td rowspan=1 colspan=1>300</td></tr><tr><td rowspan=1 colspan=1>Wondfo OxazepamUrine Test (BZO 200)</td><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>200</td></tr></table>

# e. Interference

Potential interfering substances found in human urine of physiological or pathological conditions were added to drug-free urine and target drugs urine with concentration at $2 5 \%$ below and $2 5 \%$ above Cut-Off level respectively. These urine samples were tested using three batches of each device for both Dip Card and Cup formats.

Compounds that show no interference at a concentration of $1 0 0 ~ \mu \mathrm { g / m L }$ are summarized in the following tables. There are no differences observed for both Dip Card and Cup formats.

MET 300   

<table><tr><td colspan="1" rowspan="1">Acetamidophen</td><td colspan="1" rowspan="1">Gentisic acid</td><td colspan="1" rowspan="1">Oxycodone</td></tr><tr><td colspan="1" rowspan="1">Acetophenetidin</td><td colspan="1" rowspan="1">Glucuronide</td><td colspan="1" rowspan="1">Oxymetazoline</td></tr><tr><td colspan="1" rowspan="1">N-Acetylprocainamide</td><td colspan="1" rowspan="1">Glutethimide</td><td colspan="1" rowspan="1">Papaverine</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylate</td><td colspan="1" rowspan="1">Guaifenesin</td><td colspan="1" rowspan="1">Penicillin-G</td></tr><tr><td colspan="1" rowspan="1">Aminopyrine</td><td colspan="1" rowspan="1">Hippuric acid</td><td colspan="1" rowspan="1">Pentazocine</td></tr><tr><td colspan="1" rowspan="1">Amitryptyline</td><td colspan="1" rowspan="1">Hydralazine</td><td colspan="1" rowspan="1">Pentobarbital</td></tr><tr><td colspan="1" rowspan="1">Amobarbital</td><td colspan="1" rowspan="1">Hydrochlorothiazide</td><td colspan="1" rowspan="1">Perphenazine</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">Phencyclidine</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">Hydrocortisone</td><td colspan="1" rowspan="1">Phenelzine</td></tr><tr><td colspan="1" rowspan="1">Apomorphine</td><td colspan="1" rowspan="1">O-Hydroxyhippuric acid</td><td colspan="1" rowspan="1">Phenobarbital</td></tr><tr><td colspan="1" rowspan="1">Aspartame</td><td colspan="1" rowspan="1">3-Hydroxytyramine</td><td colspan="1" rowspan="1">Prednisolone</td></tr><tr><td colspan="1" rowspan="1">Atropinne</td><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">Phenylpropanolamine</td></tr><tr><td colspan="1" rowspan="1">Benzilic acid</td><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">Prednisone</td></tr><tr><td colspan="1" rowspan="1">Benzoic acid</td><td colspan="1" rowspan="1">(-) Isoproterenol</td><td colspan="1" rowspan="1">Procaine</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">Isoxsuprine</td><td colspan="1" rowspan="1">Promazine</td></tr><tr><td colspan="1" rowspan="1">Butabartital</td><td colspan="1" rowspan="1">Ketamine</td><td colspan="1" rowspan="1">Promethazine</td></tr><tr><td colspan="1" rowspan="1">Cannabidiol</td><td colspan="1" rowspan="1">Ketoprofen</td><td colspan="1" rowspan="1">D,L-Propanolol</td></tr><tr><td colspan="1" rowspan="1">Chloralhydrate</td><td colspan="1" rowspan="1">Labetalol</td><td colspan="1" rowspan="1">D-Propoxyphene</td></tr><tr><td colspan="1" rowspan="1">Chloramphenicol</td><td colspan="1" rowspan="1">Levorphanol</td><td colspan="1" rowspan="1">D-Pseudoephedrine</td></tr><tr><td colspan="1" rowspan="1">Chlordiazepoxide</td><td colspan="1" rowspan="1">Loperamide</td><td colspan="1" rowspan="1">Quinidine</td></tr><tr><td colspan="1" rowspan="1">Chlorothiazide</td><td colspan="1" rowspan="1">Loxapine succinate</td><td colspan="1" rowspan="1">Quinine</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">Maprotiline</td><td colspan="1" rowspan="1">Ranitidine</td></tr><tr><td colspan="1" rowspan="1">Cholesterol</td><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">Salicylic acid</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">Meprobamate</td><td colspan="1" rowspan="1">Secobarbital</td></tr><tr><td colspan="1" rowspan="1">Clonidine</td><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">Serotonin(5- Hydroxytyramine)</td></tr><tr><td colspan="1" rowspan="1">Cocaine hydrochloride</td><td colspan="1" rowspan="1">Methaqualone</td><td colspan="1" rowspan="1">Sulfamethazine</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">Methylphenidal</td><td colspan="1" rowspan="1">Sulindac</td></tr><tr><td colspan="1" rowspan="1">Cortisone</td><td colspan="1" rowspan="1">Methyprylon</td><td colspan="1" rowspan="1">Temazepam</td></tr><tr><td colspan="1" rowspan="1">(-) Cotinine</td><td colspan="1" rowspan="1">Morphine-3-β-Dglucuronide</td><td colspan="1" rowspan="1">Tetracycline</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">Nalidixic acid</td><td colspan="1" rowspan="1">Tetrahydrocortisone,3-Acetate</td></tr><tr><td colspan="1" rowspan="1">Deoxycorticosterone</td><td colspan="1" rowspan="1">Nalorphine</td><td colspan="1" rowspan="1">Tetrahydrocortisone3 (β-D glucuronide)</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">Naloxone</td><td colspan="1" rowspan="1">Tetrahydrozoline</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">Naltrexone</td><td colspan="1" rowspan="1">Thebaine</td></tr><tr><td colspan="1" rowspan="1">Diclofenac</td><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">Thiamine</td></tr><tr><td colspan="1" rowspan="1">Diflunisal</td><td colspan="1" rowspan="1">Niacinamide</td><td colspan="1" rowspan="1">Thioridazine</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">Tolbutamine</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">Norcodein</td><td colspan="1" rowspan="1">Triamterene</td></tr><tr><td colspan="1" rowspan="1">Doxylamine</td><td colspan="1" rowspan="1">Norethindrone</td><td colspan="1" rowspan="1">Trifluoperazine</td></tr><tr><td colspan="1" rowspan="1">Ecgonine hydrochloride</td><td colspan="1" rowspan="1">Noroxymorphone</td><td colspan="1" rowspan="1">Trimethoprim</td></tr><tr><td colspan="1" rowspan="1">Ecgonine methyl ester</td><td colspan="1" rowspan="1">D-Norpropoxyphene</td><td colspan="1" rowspan="1">Trimipramine</td></tr><tr><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">Noscapine</td><td colspan="1" rowspan="1">D, L-Tryptophan</td></tr><tr><td colspan="1" rowspan="1">β-Estradiol</td><td colspan="1" rowspan="1">Nylidrin</td><td colspan="1" rowspan="1">Tyramine</td></tr><tr><td colspan="1" rowspan="1">Estrone-3-sulfate</td><td colspan="1" rowspan="1">D,L-Octopamine</td><td colspan="1" rowspan="1">D, L-Tyrosine</td></tr><tr><td colspan="1" rowspan="1">Ethyl-p-aminobenzoate</td><td colspan="1" rowspan="1">Oxalic acid</td><td colspan="1" rowspan="1">Uric acid</td></tr><tr><td colspan="1" rowspan="1">Fenoprofen</td><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">Verapamil</td></tr><tr><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">Oxolinic acid</td><td colspan="1" rowspan="1">Zomepirac</td></tr></table>

Oxazepam BZO 200   

<table><tr><td colspan="1" rowspan="1">4-Acetamidophenol</td><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">Oxalic acid</td></tr><tr><td colspan="1" rowspan="1">Acetophenetidin</td><td colspan="1" rowspan="1">Doxylamine</td><td colspan="1" rowspan="1">Oxolinic acid</td></tr><tr><td colspan="1" rowspan="1">N-Acetvprocainamide</td><td colspan="1" rowspan="1">Ecaonine dydrochloride</td><td colspan="1" rowspan="1">Pentobarbital</td></tr><tr><td colspan="1" rowspan="1">Acetvsalicvlic acid</td><td colspan="1" rowspan="1">Ecqonine methylester</td><td colspan="1" rowspan="1">Perphenazine</td></tr><tr><td colspan="1" rowspan="1">Aminopvrine</td><td colspan="1" rowspan="1">(-)-Y-Ephedrine</td><td colspan="1" rowspan="1">Phencyclidine</td></tr><tr><td colspan="1" rowspan="1">Amityptvline</td><td colspan="1" rowspan="1">Fenoprofen</td><td colspan="1" rowspan="1">Phenelzine.</td></tr><tr><td colspan="1" rowspan="1">Amorbarbital</td><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">Phenobarbital</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">Gentisic acid</td><td colspan="1" rowspan="1">Phentermine</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">L-Phenylephrine</td></tr><tr><td colspan="1" rowspan="1">1-Ascorbic Acid</td><td colspan="1" rowspan="1">Hydrocortisone</td><td colspan="1" rowspan="1">b-Phenylethylamine</td></tr><tr><td colspan="1" rowspan="1">D.L-Amphetamine</td><td colspan="1" rowspan="1">O-Hydroxyhippuric acid</td><td colspan="1" rowspan="1">Phenylpropanotamine</td></tr><tr><td colspan="1" rowspan="1">Apormorphine</td><td colspan="1" rowspan="1">p-Hydroxy- methamphetamine</td><td colspan="1" rowspan="1">Prednisone</td></tr><tr><td colspan="1" rowspan="1">Aspartame</td><td colspan="1" rowspan="1">3-Hydroxytyramine</td><td colspan="1" rowspan="1">D.L-Propanolol</td></tr><tr><td colspan="1" rowspan="1">Atropine</td><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">D-Propoxyphene</td></tr><tr><td colspan="1" rowspan="1">Benzillic acid</td><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">D-Pseudoephedrine</td></tr><tr><td colspan="1" rowspan="1">Benzoic acid</td><td colspan="1" rowspan="1">Iproniazid</td><td colspan="1" rowspan="1">Quinine</td></tr><tr><td colspan="1" rowspan="1">Benzoylecaonine</td><td colspan="1" rowspan="1">(±)Isoproterenol</td><td colspan="1" rowspan="1">Ranitidine</td></tr><tr><td colspan="1" rowspan="1">Benzphetamine</td><td colspan="1" rowspan="1">Isoxsuprine</td><td colspan="1" rowspan="1">Salicylic acid</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">Ketamine</td><td colspan="1" rowspan="1">Secobarbital</td></tr><tr><td colspan="1" rowspan="1">±) Chlorpheniramine</td><td colspan="1" rowspan="1">Ketoprofen</td><td colspan="1" rowspan="1">Serotonin(5-Hydroxytyramine)</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">Labetalol</td><td colspan="1" rowspan="1">Sertraline</td></tr><tr><td colspan="1" rowspan="1">Cannabidiol</td><td colspan="1" rowspan="1">Loperamide</td><td colspan="1" rowspan="1">Sulfamethazine</td></tr><tr><td colspan="1" rowspan="1">Chloralhvdrate</td><td colspan="1" rowspan="1">Maprotiline</td><td colspan="1" rowspan="1">Sulindac</td></tr><tr><td colspan="1" rowspan="1">Chloramphenicol</td><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">Tetrahydrocortisone,3 Acetate</td></tr><tr><td colspan="1" rowspan="1">Chlordiazepoxide</td><td colspan="1" rowspan="1">Meprobamate</td><td colspan="1" rowspan="1">Tetrahydrocortisone,(b-Dglucuronide)</td></tr><tr><td colspan="1" rowspan="1">Chlorothiazide</td><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">Tetrahydrozoline</td></tr><tr><td colspan="1" rowspan="1">(±)Chlorpheniramine</td><td colspan="1" rowspan="1">Methoxyphenamine</td><td colspan="1" rowspan="1">Thiamine</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">(+) 3,4-Methylenedioxy-</td><td colspan="1" rowspan="1">Thioridazine</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">amphetamine</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Chlorquine</td><td colspan="1" rowspan="1">(+)3,4-Methylenedioxy-methamphetamine</td><td colspan="1" rowspan="1">D.L-Tyrosine</td></tr><tr><td colspan="1" rowspan="1">Cholesterol</td><td colspan="1" rowspan="1">Nalidixic acid</td><td colspan="1" rowspan="1">Tolbutamide</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">Nalorphine</td><td colspan="1" rowspan="1">Triamterene</td></tr><tr><td colspan="1" rowspan="1">Clonidine</td><td colspan="1" rowspan="1">Naloxone</td><td colspan="1" rowspan="1">Trifluoperazine</td></tr><tr><td colspan="1" rowspan="1">Cocaine hydrochloride</td><td colspan="1" rowspan="1">Naltrexone</td><td colspan="1" rowspan="1">Trimethoprim</td></tr><tr><td colspan="1" rowspan="1">Cortisone</td><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">Triyptamine</td></tr><tr><td colspan="1" rowspan="1">(-)cotinine</td><td colspan="1" rowspan="1">Niacinamide</td><td colspan="1" rowspan="1">D.L-Tryptophan</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">Tyramine</td></tr><tr><td colspan="1" rowspan="1">Dextromethlorphan</td><td colspan="1" rowspan="1">Norethindrone</td><td colspan="1" rowspan="1">Uric acid</td></tr><tr><td colspan="1" rowspan="1">Diclolrfenac</td><td colspan="1" rowspan="1">D-Norpropoxyphene</td><td colspan="1" rowspan="1">Verapamil</td></tr><tr><td colspan="1" rowspan="1">Diflunisal</td><td colspan="1" rowspan="1">Noscapine</td><td colspan="1" rowspan="1">Zomepirac</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">D.L-Octopamine</td><td colspan="1" rowspan="1"></td></tr></table>

f. Specificity

To test the specificity, drug metabolites and other components that are likely to interfere in urine samples were tested using three batches of each device for both Dip Card and Cup formats. Compounds that produced positive results are listed below. There are no differences observed for both Dip Card and Cup formats.

MET 300   

<table><tr><td rowspan=1 colspan=1>MET(Methamphetamine)(D(+)-Methamphetamine, Cut-off=300 ng/mL)</td><td rowspan=1 colspan=1>MinimumConcentrationRequired toObtain aPositive Result(ng/mL)</td><td rowspan=1 colspan=1>%Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>D(+)-Methamphetamine</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>D-Amphetamine</td><td rowspan=1 colspan=1>40,000</td><td rowspan=1 colspan=1>&lt;1%</td></tr><tr><td rowspan=1 colspan=1>Chloroquine</td><td rowspan=1 colspan=1>8,000</td><td rowspan=1 colspan=1>3.8%</td></tr><tr><td rowspan=1 colspan=1>(+/-)-Ephedrine</td><td rowspan=1 colspan=1>20,000</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=1 colspan=1>(-)-Methamphetamine</td><td rowspan=1 colspan=1>8,000</td><td rowspan=1 colspan=1>3.8%</td></tr><tr><td rowspan=1 colspan=1>(+/-)3,4-methylenedioxumethamphetamine(MDMA)</td><td rowspan=1 colspan=1>800 ·</td><td rowspan=1 colspan=1>37.5%</td></tr><tr><td rowspan=1 colspan=1>β-Phenylethylamine</td><td rowspan=1 colspan=1>10,000</td><td rowspan=1 colspan=1>3%</td></tr><tr><td rowspan=1 colspan=1>Trimethobenzamide</td><td rowspan=1 colspan=1>3,000</td><td rowspan=1 colspan=1>10%</td></tr></table>

Oxazepam BZO 200   

<table><tr><td rowspan=1 colspan=1>BZO(Oxazepam)(Oxazepam, Cut-off=200 ng/mL)</td><td rowspan=1 colspan=1>MinimumConcentrationRequired to Obtain aPositive Result (ng/mL)</td><td rowspan=1 colspan=1>%Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>100%.</td></tr><tr><td rowspan=1 colspan=1>Alprazolam</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>400%</td></tr><tr><td rowspan=1 colspan=1>a-Hydroxyalprazolam</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>40%</td></tr><tr><td rowspan=1 colspan=1>Bromazepam</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>40%</td></tr><tr><td rowspan=1 colspan=1>Chlordiazepoxide</td><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>25%</td></tr><tr><td rowspan=1 colspan=1>Clonazepam HCl</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>50%</td></tr><tr><td rowspan=1 colspan=1>Clobazam</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>400%</td></tr><tr><td rowspan=1 colspan=1>Clonazepam</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>50%</td></tr><tr><td rowspan=1 colspan=1>Clorazepate dipotassium</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>400%</td></tr><tr><td rowspan=1 colspan=1>Delorazepam</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>40%</td></tr><tr><td rowspan=1 colspan=1>Desalkylflurazepam</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Diazepam</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>400%</td></tr><tr><td rowspan=1 colspan=1>Estazolam</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>20%</td></tr><tr><td rowspan=1 colspan=1>Flunitrazepam</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>D,L-Lorazepam</td><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>25%</td></tr><tr><td rowspan=1 colspan=1>Midazolam</td><td rowspan=1 colspan=1>5000</td><td rowspan=1 colspan=1>4%</td></tr><tr><td rowspan=1 colspan=1>Nitrazepam</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>400%</td></tr><tr><td rowspan=1 colspan=1>Norchlordiazepoxide</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>200%</td></tr><tr><td rowspan=1 colspan=1>Nordiazepam</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Temazepam</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>400%</td></tr><tr><td rowspan=1 colspan=1>Triazolam</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>40%</td></tr></table>

g. Effect of Urine Specified Gravity and Urine pH

To investigate the effect of urine specified gravity and urine $\mathbf { p H } ,$ the urine samples, with $1 . 0 0 0 { \sim } 1 . 0 3 5$ specified gravity or urine samples with $\tt p H \ 4 \mathrm { \sim } 9$ were spiked with target drugs at $2 5 \%$ below and $2 5 \%$ above Cut-Off level, respectively. These samples were tested using three batches of each device for both Dip Card and Cup formats. Results were all positive for samples at and above $+ 2 5 \%$ Cut-Off and all negative for samples at and below $- 2 5 \%$ Cut-Off. There were no differences observed for both Dip Card and Cup formats.

# 2 Comparison Studies

The method comparison for the Wondfo Methamphetamine Urine Test (MET . 300), Wondfo Oxazepam Urine Test (BZO 200) was performed in-house with three laboratory assistants. Operators ran 80 (40 negative and 40 positive) unaltered clinical samples. The samples were blind labeled and compared to GC/MS results. The results are presented in the table below:

MET 300:   

<table><tr><td rowspan=1 colspan=2>Wondfo Result</td><td rowspan=1 colspan=1>Drug-free</td><td rowspan=1 colspan=1>Low Negativeby GC/MS(Less than-50%)</td><td rowspan=1 colspan=1>Near Cut-offNegative byGC/MSkBetween -50%and Cut-off)</td><td rowspan=1 colspan=1>Near Cut-offPositive byGC/MS(Between theCut-off and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(Greater than+50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0.</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

# Dip Card Format

<table><tr><td rowspan=1 colspan=2>Wondfo Result</td><td rowspan=1 colspan=1>Drug-free</td><td rowspan=1 colspan=1>Low Negativeby GC/MS(Less than-50%)</td><td rowspan=1 colspan=1>Near Cut-offNegative byGC/MS(Between -50%and Cut-off)</td><td rowspan=1 colspan=1>Near Cut-offPositive byGC/MS(Between theCut-off and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(Greater than+50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant Results of MET 300   

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Cup FormatViewer Result</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>MET3212</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>MET3214</td><td rowspan=1 colspan=1>293</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>MET3212</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>MET3213</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>MET3062</td><td rowspan=1 colspan=1>281</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>MET3213</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>Positive</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Dip Card FormatViewerResults</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>MET3062</td><td rowspan=1 colspan=1>281</td><td rowspan=1 colspan=1>Positive</td></tr></table>

Oxazepam BZO 200:   

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Dip Card FormatViewer Results</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>MET3212</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>MET3213</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>MET3212</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>MET3213</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>MET3061</td><td rowspan=1 colspan=1>280</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>MET3062</td><td rowspan=1 colspan=1>281</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>MET3214</td><td rowspan=1 colspan=1>293</td><td rowspan=1 colspan=1>Positive</td></tr></table>

# Cup Format

<table><tr><td rowspan=1 colspan=2>Wondfo Result</td><td rowspan=1 colspan=1>Drug-free</td><td rowspan=1 colspan=1>Low Negativeby GC/MS(Less than-50%)</td><td rowspan=1 colspan=1>Near Cut-offNegative byGC/MS(Between -50%and Cut-off)</td><td rowspan=1 colspan=1>Near Cut-offPositive byGC/MS(Between theCut-off and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(Greater than+50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

# Dip Card Format

<table><tr><td rowspan=1 colspan=2>Wondfo Result</td><td rowspan=1 colspan=1>Drug-free</td><td rowspan=1 colspan=1>Low Negativeby GC/MS(Less than-50%)</td><td rowspan=1 colspan=1>Near Cut-offNegative byGC/MS(Between -50%and Cut-off)</td><td rowspan=1 colspan=1>Near Cut-offPositive byGC/MS(Between theCut-off and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(Greater than+50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant Results of Oxazepam BZO 200   

<table><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample Number</td><td colspan="1" rowspan="1">GC/MS Result</td><td colspan="1" rowspan="1">Cup FormatViewer Result</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BZO2065</td><td colspan="1" rowspan="1">182</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BZO2063</td><td colspan="1" rowspan="1">186</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BZO2063</td><td colspan="1" rowspan="1">186</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BZO2062</td><td colspan="1" rowspan="1">178</td><td colspan="1" rowspan="1">Positive</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Dip Card FormatViewer Results</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>BZ02062</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>BZO2063</td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>BZO2062</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>BZO2065</td><td rowspan=1 colspan=1>182</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>BZO2063</td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>BZO2216</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>Positive</td></tr></table>

3. Clinical Studies

Not applicable

# Conclusion

Based on the test principle and acceptable performance characteristics including precision, cut-off, interference, specificity and method comparison of the devices, it's concluded that Wondfo Methamphetamine Urine Test (MET 300) and Wondfo Oxazepam Urine Test (BZO 200) are substantially equivalent to the predicate.

September 27, 2013

Guangzhou Wondfo Biotech Co., Ltd. c/o Joe Shia   
504 East Diamond Ave.   
Suite F   
GAITHERSBURG MD 20878

Re: K132630 Trade/Device Name: Wondfo Methamphetamine Urine Test (MET 300) Wondfo Oxazepam Urine Test (BZO 200): Regulation Number: 21 CFR 862.3610 Regulation Name: Methamphetamine test system Regulatory Class: I1 Product Code: DJC, JXM Dated: August 11, 2013 Received: August 22, 2013

Dear Mr. Shia:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the-enactment date of the Medical Device Amendments, or to i ave ee ca t  n  l o and Cosmetic Act (Act) thal do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability rrWe   v ha vi b ust tnd o i.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Intcrnet address http:/www.fda.gov/MedicalDevices/ResoureesforYou/Industry/default.htm. Also, please note the regulation entied, "Misranding by reernce o premarket notification" (1 P 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http:/www.Ida.gov/McdicalDevices/Safctv/ReportaProblcm/default.htm for the CDRH's Office of Surveillance and Biometris/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/McdicalDeviccs/ResourcesforYou/Industry/default.htm.

Sincercly yours,

# Courtney H. Lias, Ph.D.

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): k132630

# Device Name: Wondfo Methamphetamine Urine Test (MET 300) Wondfo Oxazepam Urine Test (BZO 200)

Indications for Use:

Wondfo Methamphetamine Urine Test (MET 300)

Wondfo Methamphetamine Urine Test (MET 300) is an immunochromatographic assay for the qualitative determination of $\mathbf { D } ( + )$ -Methamphetamine in human urine at a Cut-Off concentration of $3 0 0 ~ \mathrm { n g / m L }$ . The test is available in a Dip Card format and a Cup format. This product is only intended for prescription use and is not intended for point-of-care use.

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

# Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OlR)

# Indications for Use

510(k) Number (if known): k132630

# Device Name: Wondfo Methamphetamine Urine Test (MET 300) Wondfo Oxazepam Urine Test (BZO 200)

Indications for Use:

Wondfo Oxazepam Urine Test (BZO 200)

Wondfo Oxazepam Urine Test (BzO 200) is an immunochromatographic assay for the qualitative determination of Oxazepam in human urine at a Cut-Off concentration of 200 ${ \mathfrak { n g } } / { \mathfrak { m L } }$ . The test is available in a Dip Card format and a Cup format. This product is only intended for prescription use and is not intended for point-of-care use.

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

# Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

Denise Johnson-lyles -S 2013.09.27 12:56:48 -04'00'